Cabbacis Files “X95” Worldwide Trademark Applications for Very-Low-Nicotine Cigarette Brand

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBLEND™ and X95™ brand names, today announced that it has filed worldwide trademark applications for its X95™ cigarette brand.

X95 is a patent-pending, very-low-nicotine, tobacco cigarette without any hemp and contains approximately 95 percent less nicotine than commercial cigarette brands.

Cabbacis has filed trademark applications for X95™ in the United States and numerous international markets: Europe, the United Kingdom, China, Japan, India, Indonesia, the Philippines, South Korea, Australia, New Zealand, Canada, Mexico, Chile and Brazil.

Cabbacis has also purchased and secured various “X95” domain names for the brand’s forthcoming website, including X95.world and X95cigs.com.

Joseph Pandolfino, Chief Executive Officer of Cabbacis, commented, “Although iBLEND, which contains a blend of very-low-nicotine tobacco and hemp, remains the Company’s flagship brand delivering superior taste and sensory characteristics compared to very-low-nicotine cigarettes without hemp as demonstrated in focus group testing, we believe it’s important for Cabbacis to offer both types of products worldwide. Further, X95 will fill in any distribution gaps in markets where tobacco products with hemp may not be permitted.”

About Cabbacis

Cabbacis (OTCQB: CABI) is focused on commercializing groundbreaking, patented risk-reduction tobacco products for the world's one billion smokers. Led by its flagship iBLEND™ very-low-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBLEND™ predominantly contains very-low-nicotine tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, reducing nicotine exposure and dependence, transitioning to less harmful, non-combustible tobacco products, and/or increasing quit attempts. The Company also plans to commercialize X95™, a very-low-nicotine tobacco cigarette without hemp, and separately, vaporizer pods containing hemp and conventional-nicotine content tobacco.

Cabbacis holds a global patent portfolio of 36 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets where approximately two-thirds of the world's smokers reside, including the United States, Europe, China, Japan, India, Indonesia, Russia, the Philippines, South Korea, Australia, New Zealand, Canada, Mexico and Brazil.

To learn more, please visit cabbacis.com or follow us on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate, “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in "Risk Factors" in our Regulation A Offering Circular qualified by the SEC on November 24, 2025 and in our Annual Report on Form 1-K for the year ended December 31, 2025 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.